Gokce Yildirim-Buharalioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gokce Yildirim-Buharalioglu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cuneyt Kemal Buharalioglu
İzmir Katip Çelebi Üniversitesi
2 shared publications - Recep İlHan
Department of Biochemistry, Faculty of Pharmacy, Ege University, 35040 İzmir, Turkey
2 shared publications - Ahmet Emir
Department of Pharmacognosy, Faculty of Pharmacy, Ege University, İzmir, Turkey
1 shared publication - Andrew C. Newby
School of Translational Health Sciences, Faculty of Health Sciences, University of Bristol, Research Floor Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK
1 shared publication - Ceren Emir
Department of Pharmacognosy, Faculty of Pharmacy, Ege University, 35040 İzmir, Turkey
1 shared publication - Graciela B. Sala-Newby
Chair of Vascular Cell Biology, School of Clinical Sciences, University of Bristol, Bristol, UK
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (6) , 2691
Targeted and Untargeted Metabolomics and Pharmacological Potential of Endemic Stachys sparsipilosa R. Bhattacharjee & Hub.-Mor.
Species of the genus Stachys (Lamiaceae) are recognized for their ethnobotanical importance and chemical diversity. In this study, the essential oil (EOS) and solvent extracts of the endemic species Stachys sparsipilosa were investigated using integrated GC–MS and LC–ESI–QTOF/MS approaches. GC–MS analysis showed that identified constituents accounted for 94.62% of the total oil, with caryophyllene oxide, kauran-16-ol, and cubebol as major components. Targeted LC–MS analysis quantified prominent phenolic compounds, including chlorogenic acid, rutin, and hesperidin, while untargeted metabolomics tentatively annotated 168 metabolites belonging to phenolics, terpenoids, and other classes. Antioxidant capacity was evaluated using complementary in vitro assays, and enzyme inhibitory activities against α-amylase, α-glucosidase, tyrosinase, acetylcholinesterase, and butyrylcholinesterase were assessed in comparison with standard inhibitors. The extracts demonstrated measurable but generally moderate activities relative to the corresponding positive controls. The essential oil exhibited moderate, non-selective cytotoxic effects at relatively high concentrations, whereas solvent extracts showed limited activity within the tested range. Molecular docking analyses were performed as supportive tools to explore possible enzyme–ligand interactions. Overall, S. sparsipilosa displays a chemically diverse metabolite profile associated with composition-dependent bioactivities, providing a basis for further mechanistic and in vivo studies.
- 11 March 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (6) , 2691
Open AccessTargeted and Untargeted Metabolomics and Pharmacological Potential of Endemic Stachys sparsipilosa R. Bhattacharjee & Hub.-Mor.
Species of the genus Stachys (Lamiaceae) are recognized for their ethnobotanical importance and chemical diversity. In this study, the essential oil (EOS) and solvent extracts of the endemic species Stachys sparsipilosa were investigated using integrated GC–MS and LC–ESI–QTOF/MS approaches. GC–MS analysis showed that identified constituents accounted for 94.62% of the total oil, with caryophyllene oxide, kauran-16-ol, and cubebol as major components. Targeted LC–MS analysis quantified prominent phenolic compounds, including chlorogenic acid, rutin, and hesperidin, while untargeted metabolomics tentatively annotated 168 metabolites belonging to phenolics, terpenoids, and other classes. Antioxidant capacity was evaluated using complementary in vitro assays, and enzyme inhibitory activities against α-amylase, α-glucosidase, tyrosinase, acetylcholinesterase, and butyrylcholinesterase were assessed in comparison with standard inhibitors. The extracts demonstrated measurable but generally moderate activities relative to the corresponding positive controls. The essential oil exhibited moderate, non-selective cytotoxic effects at relatively high concentrations, whereas solvent extracts showed limited activity within the tested range. Molecular docking analyses were performed as supportive tools to explore possible enzyme–ligand interactions. Overall, S. sparsipilosa displays a chemically diverse metabolite profile associated with composition-dependent bioactivities, providing a basis for further mechanistic and in vivo studies.
- 1 August 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-17
Epigenetic regulation of TIMP-3 expression in human macrophages via physiological and pharmacological modification of histone3 lysine27 (H3K27)
Background Tissue inhibitor of metalloproteinases-3 (TIMP-3) prevents over-activity of metalloproteinases, thereby reducing the severity of several immune/ inflammatory diseases in which T-lymphocyte-stimulated macrophage invasion plays an essential role. However, the underlying mechanism of TIMP-3 expression and its modulation by anti-inflammatory agents are poorly understood. Methods and results Using RT-qPCR measurements in human macrophages, we showed that TIMP-3 steady-state and pre-spliced mRNAs are induced by the Thelper2 cytokine, interleukin-4 (IL-4) but downregulated by the pro-inflammatory Thelper1 cytokine, interferon-γ (IFN-γ), an inhibitory effect confirmed at the protein level. These effects of IL-4 and IFN-γ were independent of changes in the lineage determining transcription factors, CEBP-β, SP-1 and PU1/ETS, suggesting that epigenetic regulation might be important. We investigated the action of GSK-J4, an inhibitor of the histone3 lysine27 (H3K27) demethylase (KDM6) enzymes. GSK-J4 decreased basal and IL-4 induced TIMP-3 levels, concomitant with increased H3K27 tri-methylation (H3K27me3) by Chromatin Immunoprecipitation. Moreover, using adenovirus-mediated silencing, TIMP-3 expression was found to be specifically regulated by KDM6B. GSK-J4 had no effect on IFN-γ induced inhibition of TIMP-3 mRNA, which was instead accompanied by a fall in H3K27 acetylation at the TIMP-3 promoter. The histone deacetylase (HDAC) inhibitor, MS-275, completely reversed this fall and partially restored TIMP-3 expression. Conclusions In conclusion GSK-J4 reduces TIMP-3 expression and might therefore paradoxically increase macrophage invasion. By contrast, the HDAC inhibitor MS-275 antagonised the depression of TIMP-3 expression by IFN-γ, which should reduce macrophage invasion.
- 1 August 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-17
Epigenetic regulation of TIMP-3 expression in human macrophages via physiological and pharmacological modification of histone3 lysine27 (H3K27)
Background Tissue inhibitor of metalloproteinases-3 (TIMP-3) prevents over-activity of metalloproteinases, thereby reducing the severity of several immune/ inflammatory diseases in which T-lymphocyte-stimulated macrophage invasion plays an essential role. However, the underlying mechanism of TIMP-3 expression and its modulation by anti-inflammatory agents are poorly understood. Methods and results Using RT-qPCR measurements in human macrophages, we showed that TIMP-3 steady-state and pre-spliced mRNAs are induced by the Thelper2 cytokine, interleukin-4 (IL-4) but downregulated by the pro-inflammatory Thelper1 cytokine, interferon-γ (IFN-γ), an inhibitory effect confirmed at the protein level. These effects of IL-4 and IFN-γ were independent of changes in the lineage determining transcription factors, CEBP-β, SP-1 and PU1/ETS, suggesting that epigenetic regulation might be important. We investigated the action of GSK-J4, an inhibitor of the histone3 lysine27 (H3K27) demethylase (KDM6) enzymes. GSK-J4 decreased basal and IL-4 induced TIMP-3 levels, concomitant with increased H3K27 tri-methylation (H3K27me3) by Chromatin Immunoprecipitation. Moreover, using adenovirus-mediated silencing, TIMP-3 expression was found to be specifically regulated by KDM6B. GSK-J4 had no effect on IFN-γ induced inhibition of TIMP-3 mRNA, which was instead accompanied by a fall in H3K27 acetylation at the TIMP-3 promoter. The histone deacetylase (HDAC) inhibitor, MS-275, completely reversed this fall and partially restored TIMP-3 expression. Conclusions In conclusion GSK-J4 reduces TIMP-3 expression and might therefore paradoxically increase macrophage invasion. By contrast, the HDAC inhibitor MS-275 antagonised the depression of TIMP-3 expression by IFN-γ, which should reduce macrophage invasion.
- Open Access
- 28 April 2019
- Published by Mersin Universitesi Saglik Bilimleri Dergisi in Mersin Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (1) , 136-142
Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi
Bu derlemede, tarihsel bir yaklaşımla, talidomit kullanan gebelerin fokomelili bebeklerinin doğumu sonrasında yaşananlar değerlendirilerek, bu facianın sistematik farmakovijilans etkinliklerinin gelişimine etkisi araştırılmıştır. Bu amaçla, ilgili anahtar kelimeleri içeren PubMed taraması yapılarak çalışmamızın amacı ile uyumlu bilimsel makaleler ve tarihsel bilgileri içeren derlemeler çalışmamıza dahil edilmiştir. Bulgularımız teratojenisite, ilaç güvenliliği ile ilgili etik ve yasal düzenlemeler, ilaçların geliştirilmesi ve pazarlama sonrası gözetimi gibi önemli farmakovijilans etkinliklerinin gelişiminde talidomit faciasının nasıl bir itici güç olduğunu vurgulamıştır. Talidomidin kütanöz lepranın ve multipl myelomanın tedavisinde kullanılmak üzere yakın geçmişte ilaç piyasasına geri dönüşü ilaç güvenliliğine bakış açımızı değiştirmiş ve risk yönetimini ön plana çıkartmıştır. Sonuç olarak; talidomit faciasının ardından yaşananlara günümüzün gözüyle bakmak, farmakovijilans etkinliklerini daha iyi anlamamızı sağlamakla birlikte önümüzdeki yıllarda farmakovijilansı bekleyen zorlukları belirleyip çözmemize yardımcı olma potansiyelini de taşımaktadır.
- 28 April 2019
- Published by Mersin Universitesi Saglik Bilimleri Dergisi in Mersin Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (1) , 136-142
Open AccessTalidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi
Bu derlemede, tarihsel bir yaklaşımla, talidomit kullanan gebelerin fokomelili bebeklerinin doğumu sonrasında yaşananlar değerlendirilerek, bu facianın sistematik farmakovijilans etkinliklerinin gelişimine etkisi araştırılmıştır. Bu amaçla, ilgili anahtar kelimeleri içeren PubMed taraması yapılarak çalışmamızın amacı ile uyumlu bilimsel makaleler ve tarihsel bilgileri içeren derlemeler çalışmamıza dahil edilmiştir. Bulgularımız teratojenisite, ilaç güvenliliği ile ilgili etik ve yasal düzenlemeler, ilaçların geliştirilmesi ve pazarlama sonrası gözetimi gibi önemli farmakovijilans etkinliklerinin gelişiminde talidomit faciasının nasıl bir itici güç olduğunu vurgulamıştır. Talidomidin kütanöz lepranın ve multipl myelomanın tedavisinde kullanılmak üzere yakın geçmişte ilaç piyasasına geri dönüşü ilaç güvenliliğine bakış açımızı değiştirmiş ve risk yönetimini ön plana çıkartmıştır. Sonuç olarak; talidomit faciasının ardından yaşananlara günümüzün gözüyle bakmak, farmakovijilans etkinliklerini daha iyi anlamamızı sağlamakla birlikte önümüzdeki yıllarda farmakovijilansı bekleyen zorlukları belirleyip çözmemize yardımcı olma potansiyelini de taşımaktadır.